The Chimeric Investigator

The Chimeric Investigator

Onlangs schreven Huib Vriesendorp en Hal Drooglever Fortuyn het artikel: The Chimeric Investigator, an Endangered Species. Met daarin: 'A Chimeric Investigator has both an MD ‘genotype’ and an Investigator ‘genotype’: a good starting point for translating serious problems of patients into an ‘experimental’ question.'  Lees…

Lees Meer
P2T Publicatie Graft Versus Host Disease

P2T publicatie Graft versus Host Disease

Phase2Therapy geeft met vreugde kennis van de geboorte van het artikel ‘History of Graft versus Host Disease’ (historie van transplantaat tegen ontvanger ziekte, GvHD), geschreven door  twee leden van het P2T bestuur: Huib Vriesendorp en Peter Heidt. Deze publicatie is te…

Lees Meer

History of Graft-versus-Host Disease

Huib M. Vriesendorp, MD, PhD1,2 and Peter J. Heidt, PhD1,3 1 Phase2Therapy, Den Haag, The Netherlands, hvriesendorp@gmail.com 2 PO Box 2855, Silverthorne, CO, 80498, USA 3 Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands

Lees Meer

Of scientific physicians and evidence-based medicine

In regard to Glatstein, IJROBP 2001;49:619–621  Huib M. Vriesendorp M.D., Ph.D. Marshfield Clinic Marshfield, WI, USA Quand on n’a pas du charactere, il vaut bien prendre une methode. [Lack of Character is best compensated by a method] Albert Camus, La Chute [The…

Lees Meer

Prediction of normal tissue damage induced by cancer chemotherapy

Huibert Michiel Vriesendorp, Rob Vriesendorp, Francine Vriesendorp. University of Maryland, School of Medicine and Hospital Cancer Chemotherapy and Pharmacology (Impact Factor: 2.57).  02/1987; 19(4):273-6. DOI: 10.1007/BF00261471 Cancer chemotherapeutic agents have a low therapeutic index and require a precise and safe prescription. Hematological toxicity…

Lees Meer
Search